Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HCM HUTCHMED	$17.82 +1.3%	$15.15	$11.51 ▼ $21.50	$3.11B	0.52	91,228 shs	10,483 shs
KYMR Kymera Therapeutics	$46.43 +0.5%	$40.99	$19.45 ▼ $53.27	$3.03B	2.18	616,249 shs	131,726 shs
MOR MorphoSys	$18.96	$18.96	$4.18 ▼ $19.50	$2.86B	1.2	1.02 million shs	N/A
NUVB Nuvation Bio	$2.36 +2.4%	$2.15	$1.54 ▼ $3.97	$801.31M	1.33	3.12 million shs	1.86 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HCM HUTCHMED	0.00%	+9.66%	+18.53%	+26.64%	-7.13%
KYMR Kymera Therapeutics	0.00%	+3.82%	+0.68%	+70.03%	+7.15%
MOR MorphoSys	0.00%	0.00%	0.00%	0.00%	+1.44%
NUVB Nuvation Bio	0.00%	+5.00%	+18.16%	+16.37%	-23.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HCM HUTCHMED	0.6852 of 5 stars	1.0	3.0	0.0	0.0	0.6	0.0	1.9
KYMR Kymera Therapeutics	3.1599 of 5 stars	4.5	1.0	0.0	0.0	3.2	2.5	0.0
MOR MorphoSys	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NUVB Nuvation Bio	2.8576 of 5 stars	4.6	0.0	0.0	0.0	1.1	4.2	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HCM HUTCHMED	2.00	Hold	$19.00	6.62% Upside
KYMR Kymera Therapeutics	3.05	Buy	$59.11	27.30% Upside
MOR MorphoSys	0.00	N/A	N/A	N/A
NUVB Nuvation Bio	3.20	Buy	$7.17	204.32% Upside

Current Analyst Ratings Breakdown

Latest NUVB, KYMR, MOR, and HCM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	KYMR Kymera Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/3/2025	KYMR Kymera Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$70.00
6/27/2025	KYMR Kymera Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$56.00 ➝ $53.00
6/26/2025	KYMR Kymera Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$59.00
6/26/2025	KYMR Kymera Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$57.00 ➝ $53.00
6/26/2025	KYMR Kymera Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $60.00
6/25/2025	KYMR Kymera Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$64.00
6/25/2025	NUVB Nuvation Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
6/17/2025	NUVB Nuvation Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$10.00 ➝ $6.00
6/11/2025	NUVB Nuvation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$5.00
6/3/2025	KYMR Kymera Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00

(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HCM HUTCHMED	$630.20M	4.93	$0.29 per share	61.24	$4.43 per share	4.02
KYMR Kymera Therapeutics	$47.07M	64.24	N/A	N/A	$12.90 per share	3.60
MOR MorphoSys	$238.28M	11.99	N/A	N/A	$0.35 per share	54.17
NUVB Nuvation Bio	$7.87M	101.82	N/A	N/A	$1.37 per share	1.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HCM HUTCHMED	$37.73M	N/A	0.00	12.21	N/A	N/A	N/A	N/A	8/7/2025 (Estimated)
KYMR Kymera Therapeutics	-$223.86M	-$3.10	N/A	N/A	N/A	-409.07%	-30.11%	-25.65%	8/6/2025 (Estimated)
MOR MorphoSys	-$205.35M	-$3.48	N/A	N/A	N/A	-226.79%	-694.31%	-22.55%	N/A
NUVB Nuvation Bio	-$567.94M	-$2.35	N/A	N/A	N/A	-5,534.21%	-44.14%	-32.97%	8/4/2025 (Estimated)

Latest NUVB, KYMR, MOR, and HCM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	KYMR Kymera Therapeutics	-$0.84	N/A	N/A	N/A	$17.37 million	N/A
8/4/2025	Q2 2025	NUVB Nuvation Bio	-$0.17	N/A	N/A	N/A	$0.42 million	N/A
5/9/2025	Q1 2025	KYMR Kymera Therapeutics	-$0.92	-$0.82	+$0.10	-$0.82	$11.38 million	$22.10 million
5/7/2025	Q1 2025	NUVB Nuvation Bio	-$0.16	-$0.16	N/A	-$0.16	$0.42 million	$3.08 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HCM HUTCHMED	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A
MOR MorphoSys	N/A	N/A	N/A	N/A	N/A
NUVB Nuvation Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HCM HUTCHMED	0.08	2.83	2.70
KYMR Kymera Therapeutics	N/A	8.49	8.49
MOR MorphoSys	4.98	1.38	1.38
NUVB Nuvation Bio	N/A	9.01	9.01

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HCM HUTCHMED	8.82%
KYMR Kymera Therapeutics	N/A
MOR MorphoSys	18.38%
NUVB Nuvation Bio	61.67%

Insider Ownership

Company	Insider Ownership
HCM HUTCHMED	3.60%
KYMR Kymera Therapeutics	16.01%
MOR MorphoSys	0.05%
NUVB Nuvation Bio	29.93%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HCM HUTCHMED	1,811	174.42 million	168.14 million	Not Optionable
KYMR Kymera Therapeutics	170	65.12 million	54.69 million	Optionable
MOR MorphoSys	730	150.62 million	150.55 million	Not Optionable
NUVB Nuvation Bio	60	340.26 million	238.42 million	Optionable

NUVB, KYMR, MOR, and HCM Headlines

Recent News About These Companies

Nuvation Bio (NYSE:NUVB) Trading Up 5.4% - What's Next?

July 16, 2025 | marketbeat.com

Nuvation Bio (NYSE:NUVB) Stock Price Down 5.2% - Should You Sell?

July 14, 2025 | marketbeat.com

All You Need to Know About Nuvation Bio (NUVB) Rating Upgrade ... - Nasdaq

July 11, 2025 | nasdaq.com

All You Need to Know About Nuvation Bio (NUVB) Rating Upgrade to Buy

July 9, 2025 | zacks.com

Nuvation Bio (NYSE:NUVB) Shares Gap Up - What's Next?

July 9, 2025 | marketbeat.com

Nuvation Bio Inc. (NYSE:NUVB) Receives Consensus Recommendation of "Buy" from Brokerages

July 7, 2025 | marketbeat.com

Nuvation Bio Inc. (NUVB) latest stock news and headlines - Yahoo Finance

July 2, 2025 | uk.finance.yahoo.com

Nuvation Bio (NYSE:NUVB) Stock Price Up 8% - Time to Buy?

June 30, 2025 | marketbeat.com

JMP Maintains “Market Outperform” on Nuvation (NUVB) for IBTROZI Launch Plans

June 29, 2025 | msn.com

Nuvation Bio (NYSE:NUVB) Sees Strong Trading Volume - Here's What Happened

June 25, 2025 | marketbeat.com

Nuvation Bio's (NUVB) "Market Outperform" Rating Reaffirmed at JMP Securities

June 25, 2025 | marketbeat.com

RBC Capital Lowers PT on Nuvation Bio (NUVB) to $6 But Keeps a Buy Rating

June 24, 2025 | msn.com

Nuvation Bio jumps after insiders purchase shares worth over $1.1M

June 20, 2025 | msn.com

Founder of Nuvation Bio David Hung Buys More Stock

June 20, 2025 | finance.yahoo.com

Nuvation Bio price target lowered to $6 from $10 at RBC Capital

June 18, 2025 | investing.com

Nuvation Bio: A Justified Fall Based On Post-Marketing Requirements

June 18, 2025 | seekingalpha.com

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc.

June 16, 2025 | globenewswire.com

Nuvation Bio price target maintained at $6 by Citizens JMP

June 14, 2025 | investing.com

Nuvation Bio’s SWOT analysis: FDA approval boosts stock prospects

June 14, 2025 | investing.com

Nuvation Bio Stock Short Interest Report | NYSE:NUVB | Benzinga

June 13, 2025 | benzinga.com

US FDA approves Nuvation Bio's rare lung cancer drug

June 13, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

D-Wave Is Rising Again Despite Dilution—What’s the Deal?
By Nathan Reiff | July 7, 2025
View D-Wave Is Rising Again Despite Dilution—What’s the Deal?
More Than a Monetary Metal: Silver's Case for Outperformance
By Jeffrey Neal Johnson | June 22, 2025
View More Than a Monetary Metal: Silver's Case for Outperformance
Don’t Miss Out: 3 Blue-Chips Set to Pop This Earnings Season
By Chris Markoch | July 8, 2025
View Don’t Miss Out: 3 Blue-Chips Set to Pop This Earnings Season
3 Stocks Hitting All-Time Highs With More Room to Run
By Dan Schmidt | June 27, 2025
View 3 Stocks Hitting All-Time Highs With More Room to Run
Big Bank Buybacks: Morgan Stanley, Citi, & Wells Fargo Lead
By Gabriel Osorio-Mazilli | July 3, 2025
View Big Bank Buybacks: Morgan Stanley, Citi, & Wells Fargo Lead

NUVB, KYMR, MOR, and HCM Company Descriptions

HUTCHMED NASDAQ:HCM

$17.82 +0.23 (+1.31%)

As of 11:52 AM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Kymera Therapeutics NASDAQ:KYMR

$46.43 +0.25 (+0.55%)

As of 11:52 AM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)

As of 07/18/2025

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Nuvation Bio NYSE:NUVB

$2.36 +0.06 (+2.39%)

As of 11:51 AM Eastern

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time